Enfusion, Inc. (NYSE:ENFN) Director Deirdre Somers Sells 1,637 Shares

Enfusion, Inc. (NYSE:ENFN) Director Deirdre Somers sold 1,637 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.53, for a total transaction of $17,237.61. Following the completion of the sale, the director now owns 41,675 shares of the company’s stock, valued at approximately $438,837.75. This represents a 3.78 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Enfusion Trading Up 0.9 %

NYSE ENFN traded up $0.10 during trading on Wednesday, reaching $10.91. The company’s stock had a trading volume of 1,645,948 shares, compared to its average volume of 1,406,472. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of 272.82, a price-to-earnings-growth ratio of 3.98 and a beta of 0.95. Enfusion, Inc. has a 12 month low of $7.52 and a 12 month high of $11.38. The firm has a 50 day moving average price of $10.19 and a 200 day moving average price of $9.23.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ENFN shares. Piper Sandler boosted their price target on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. William Blair reiterated a “market perform” rating on shares of Enfusion in a research note on Monday. Finally, Stifel Nicolaus raised their price objective on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Three analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Enfusion has an average rating of “Hold” and a consensus price target of $10.25.

Institutional Trading of Enfusion

A number of institutional investors have recently modified their holdings of ENFN. TenCore Partners LP acquired a new position in Enfusion in the third quarter valued at about $3,938,000. Dimensional Fund Advisors LP boosted its position in shares of Enfusion by 57.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 524,142 shares of the company’s stock worth $4,466,000 after acquiring an additional 191,436 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Enfusion by 612.4% in the third quarter. JPMorgan Chase & Co. now owns 208,022 shares of the company’s stock valued at $1,974,000 after acquiring an additional 178,821 shares during the last quarter. Impax Asset Management Group plc raised its position in Enfusion by 25.4% during the third quarter. Impax Asset Management Group plc now owns 676,948 shares of the company’s stock valued at $6,424,000 after purchasing an additional 136,948 shares in the last quarter. Finally, Scalar Gauge Management LLC lifted its stake in Enfusion by 21.8% during the second quarter. Scalar Gauge Management LLC now owns 613,513 shares of the company’s stock worth $5,227,000 after purchasing an additional 110,000 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.